rs80359629
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.6944_6947del(p.Ile2315LysfsTer12) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000206 in 1,453,294 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. T2314T) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000059.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.6944_6947del | p.Ile2315LysfsTer12 | frameshift_variant | 13/27 | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.6944_6947del | p.Ile2315LysfsTer12 | frameshift_variant | 13/27 | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD3 exomes AF: 0.00000801 AC: 2AN: 249558Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134970
GnomAD4 exome AF: 0.00000206 AC: 3AN: 1453294Hom.: 0 AF XY: 0.00000138 AC XY: 1AN XY: 723148
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | May 29, 2002 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Feb 29, 2012 | - - |
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Apr 22, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Sep 22, 2014 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 14, 2019 | The p.Ile2315LysfsX12 variant in BRCA2 has been reported in at least 15 families with breast and/or ovarian cancer (Frank 1998, Wong-Brown 2015, Evans 2008, Teer 2016, BIC database). It has also been identified in 2/113008 European chromosomes by gnomAD (http://gnomad.broadinstitute.org); however, this frequency is low enough to be consistent with the frequency of hereditary breast and ovarian cancer (HBOC) in the general population. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 2315 and leads to a premature termination codon 12 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the BRCA2 gene is an established disease mechanism in autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC). Additionally, this variant was classified as Pathogenic on Sept 8, 2016 by the ClinGen-approved ENIGMA expert panel (Variation ID: 91435). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PVS1, PM2, PS4_Strong. - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 18, 2024 | This sequence change creates a premature translational stop signal (p.Ile2315Lysfs*12) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs751065688, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 9667259, 25682074). This variant is also known as 7172del4. ClinVar contains an entry for this variant (Variation ID: 38075). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 01, 2021 | Variant summary: BRCA2 c.6944_6947delTAAA (p.Ile2315LysfsX12) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8e-06 in 249558 control chromosomes (gnomAD). c.6944_6947delTAAA has been reported in the literature in multiple individuals affected with breast and ovarian cancer (example: Frank_1998, Evans_2008, Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. Seven other ClinVar submitters including an expert panel (ENIGMA) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 30, 2021 | This frameshift variant causes the premature termination of BRCA2 protein synthesis. In addition, it has been identified in individuals with breast and ovarian cancer in the published literature (PMID: 9667259 (1998), 29446198 (2018), 25682074 (2015), 17636422 (2008)). Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 22, 2021 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Frank 1998, Evans 2008, Wong-Brown 2015, Huang 2018); Also known as 7172del4 and 7172delTAAA; This variant is associated with the following publications: (PMID: 29625052, 9667259, 17636422, 25682074, 28852190, 24307375, 28152038, 20167696, 30720243) - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 19, 2022 | The c.6944_6947delTAAA pathogenic mutation, located in coding exon 12 of the BRCA2 gene, results from a deletion of 4 nucleotides at nucleotide positions 6944 to 6947, causing a translational frameshift with a predicted alternate stop codon (p.I2315Kfs*12). This mutation has been reported in multiple individuals with hereditary breast and/or ovarian cancer (Evans D et al. Fam. Cancer. 2008 Jul;7:113-7; Frank T et al. J. Clin. Oncol. 1998 Jul;16:2417-25; Wong-Brown MW et al. Breast Cancer Res. Treat. 2015 Feb;150(1):71-80; Rebbeck TR et al. Hum Mutat, 2018 05;39:593-620). Of note, this alteration is also designated as 7172del4 in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 26, 2023 | This variant deletes 4 nucleotides in exon 13 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant is also known as 7172del4 or 7172delTAAA in the literature. This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 9667259, 17636422, 25682074) and has been identified in 13 families among the CIMBA participants (PMID: 29446198). This variant has been identified in 2/249558 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Familial cancer of breast Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 24, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at